The global microRNA market was estimated at US$ 2.31 billion in 2026 and is projected to grow to US$ 6.89 billion by 2035, rising at a compound annual growth rate (CAGR) of 12.89% from 2026 to 2035. The increasing prevalence of chronic conditions is driving the market’s growth.
The term "microRNA market" refers to the dynamic and quickly growing area of the biotechnology and life sciences industries that is focused on the discovery, creation, and promotion of goods and technologies based on microRNA. MicroRNAs are short, non-coding RNA molecules that are extremely conserved and have a role in controlling the expression of certain genes. miRNA is primarily involved in the control of genes. Numerous illnesses can be treated by using miRNA as targets or instruments. miRNA controls a large number of genes involved in DNA repair. In addition to identifying the diagnostic, prognostic, and/or predictive value of individual microRNAs or microRNA signatures as potential biomarkers for patient management, this enormously large body of research has produced innovative technological advancements for the detection of microRNAs in tissue and bodily fluids.
Advances in biomedical informatics' machine learning field have made it possible to investigate medications that target miRNA, therefore advancing the field of miRNA therapies. Additionally, the outcomes of machine learning models' predictions might be contrasted with miRNA-disease/drug connections that have been confirmed by experimental means. The lack of data available for building trustworthy prediction models may be addressed by machine learning techniques like active learning. Machine learning fairness is a recently developed subject that aims to investigate the impact of model and data biases, such as gender, ethnicity, and disability, on the prediction performance of miRNA treatment.
For instance,
Increasing Number of Clinical Trials Drive the microRNA Market
Because miRNAs can be used as therapeutic targets in clinical settings, research on them has been concentrated. Numerous clinical trials employing miRNAs for medication testing, diagnosis, and screening are now in progress. Biopharmaceutical firms are becoming more involved in this dynamic sector, and current clinical studies suggest that anti-miR and miR-mimic medicines represent a new class of compounds with potential therapeutic uses in the future. Clinical trials for nearly all human disorders are focusing on the therapeutic potential of miRNA therapies.
For instance,
Safety & Efficiency Issues Restraint the microRNA Market
It is still difficult to determine the efficacy and safety of miRNA-based therapies, particularly those that aim to target human tissues via the administration of miRNA mimics or antagomirs. MiRNA delivery techniques have some disadvantages, including a weak binding affinity for complementary sequences, fast clearance from blood, toxicity that occurs off-target, vulnerability to nucleases upon introduction into biological systems, and off-target toxicity. Moreover, they may induce involuntary gene silencing because they target many pathways through imprecise matching in the 3′ UTR region.
microRNA Therapeutics is the future of the microRNA Market
These short RNAs offer themselves for therapeutic reasons toward a focused alteration of cell processes that are critical to a disease phenotype, in addition to the diagnostic potential of changed miRNA expression levels. Understanding the functions of miRNAs in development and illness, especially cancer, has made miRNAs desirable targets and instruments for cutting-edge treatment strategies. Numerous treatments targeting miRNA have advanced to the clinical stage. Consequently, substantial expenditures have been made in the development of miRNA-based therapeutics by multidisciplinary sectors spanning biology, chemistry, and medical research.
| Sr. No. | miRNA Therapeutics in the Preclinical Stage | miRNA Therapeutics in Clinical Stage |
| 1. | RG-012 | miR-10b |
| 2. | MGN-1347 | INT-1B3 |
| 3. | MGN-2677 | AMT-130 |
| 4. | MGN-4220 | RGLS4326 |
| 5. | MGN-4893 | MRG-110 |
| 6. | MGN-5804 | MesomiR-1 |
| 7. | MGN-6114 | CDR132L |
| 8. | MGN-9103 | RG-101 |
| 9. | MRG-107 | MRX34 |
| 10. | -- | miR-10 |
| Key Elements | Scope |
| Market Size in 2025 | USD 2.05 billion |
| Projected Market Size in 2035 | USD 6.89 billion |
| CAGR (2025 - 2035) | 12.89% |
| Leading Region | North America by 41.6% |
| Key Applications | Cancer diagnostics, infectious disease detection, neurological disorders, cardiovascular diseases, biomarker discovery, companion diagnostics, RNA therapeutics |
| Primary End Users | Biotechnology companies, pharmaceutical companies, academic institutes, hospitals, diagnostic laboratories, CROs |
| Key Challenges | Delivery of miRNA therapeutics, regulatory complexity, biomarker validation, high development costs, standardization of assays |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Products & Services, By Application, By End-use, By Region |
| Top Key Players | Thermo Fisher Scientific, Inc., DiamiR Biosciences, New England Biolabs, NanoString Technologies, Inc., Sanofi, miRecule, Alnylam, BioGenex, Merck KGaA, LGC Limited, Takara Bio, Inc., Horizon Discovery Group plc., QIAGEN, GeneCopoeia, Inc. |
| Segments | Shares % |
| Services | 58% |
| Products | 42% |
Which Products & Services Segment Dominated the microRNA Market?
By products & services, the service segment held the largest share of 58% of the microRNA market in 2025. There are different types of services associated with microRNA. Each service has different roles. Quantification of customer-provided total RNA or microRNA samples is included in the microRNA sequencing services, which also comprise microRNA library creation, cluster production, and sequencing. From sample extraction to data processing, CD Genomics' microRNA sequencing service provides complete and integrated services. Quality control for sample extraction, sequencing, library preparation, bioinformatics analysis, and data reporting are all included in the service.
| Segments | Shares % |
| Cancer | 34% |
| Infectious Diseases | 20% |
| Immunological Disorder | 14% |
| Cardiovascular Disease | 12% |
| Neurological Disease | 10% |
| Others | 10% |
Why Did the Cancer Segment Dominate the microRNA Market?
By application, the cancer segment dominated the microRNA market by 34% share in 2025. Nowadays, cancer is one of the major issues. Researchers are always looking for novel elements that contribute to the carcinogenesis process. miRNAs are thought to be possible cancer indicators. First, because miRNA molecules are found in a variety of bodily fluids, they are easily accessible for research. Second, miRNAs' great biological stability makes it easier to discover them. Third, miRNAs exhibit tissue-specific expression in many situations and control all phases of tumor formation.
For instance,
By application, the infectious diseases segment is anticipated to grow at the fastest rate in the microRNA market during the forecast period. Because extracellular miRNAs can be extracted from bodily fluids, they are excellent biomarker candidates. Ex-miRNAs in patient samples might be quantified using RT-PCR, which is currently often utilized in the clinical environment to rapidly detect infections (e.g., respiratory infections in newborns with bronchiolitis). According to a number of recent research, miRNAs have a critical role in controlling immune cell differentiation, maturation, and activation, which in turn affects how the host immune system responds to infection. miRNAs have been investigated recently in a variety of infectious illnesses as therapeutic targets and diagnostic indicators.
| Segments | Shares % |
| Biotechnology & Pharmaceutical Companies | 52% |
| Academic & Government Research Institutes | 34% |
| Others | 14% |
Which End-Use Segment Dominated the microRNA Market?
By end-use, the biotechnology & pharmaceutical companies segment dominated the microRNA market by 52% in 2025. The main function of microRNA is in therapeutics and various sequencing-associated activities. Both biotechnology and pharmaceutical companies are highly invested in the development of new therapeutics and understanding the function of genes. As the population grows, unhealthy lifestyles and environmental conditions contribute to chronic conditions, pharma, and biotech companies are conducting clinical trials and research studies. Companies are heavily investing and collaborating with other companies and government institutions to come up with better solutions.
For instance,
North America dominated the microRNA market share by 41.6% in 2025. because there is a robust biotechnology and pharmaceutical sector, a well-established healthcare infrastructure, and large expenditures in research and development. Numerous industry participants and university research centers actively involved in miRNA research are based in the region. The availability of cutting-edge technology, collaborative efforts between academia and business, and supportive government initiatives all contribute to North America's commercial supremacy in the microRNA market.
U.S. Market Trends
For instance,
By region, Asia Pacific is expected to grow at the fastest rate during the forecast period by 21% share in 2025. Some of the factors propelling the microRNA market expansion in the area include the rapidly expanding population, an increase in the prevalence of cardiovascular illnesses, a greater demand for microRNA-based treatments, and a stronger focus on research and development initiatives.
For instance,
China Market Trends
China has been a popular complementary and alternative medicine for the treatment of cancer in recent decades. MicroRNAs, or miRNAs, have been intensively studied for their potential to target miRNAs and play essential roles in several pathological processes, including cancer. Additionally, Chinese medicinal herbs have been proven to have anti-cancer properties through miRNA targeting. Drawn from the root of Coptis chinensis, berberine is a well-known herbal remedy with anti-cancer properties.
Europe is projected to grow with share of 27% share at a notable rate in the foreseeable future. The growing genomics research and the rising adoption of advanced technologies are the major growth factors of the market. The increasing prevalence of genetic and rare disorders necessitates researchers to develop advanced therapeutics tailored to patients’ requirements. Several government organizations take numerous measures for early diagnosis and disease monitoring, governing the need for microRNAs. The increasing number of clinical trials and growing investments also contribute to market growth.
France Market Trends
The Panorama France Healthtech report identifies 2,600 biotech, medtech, and digital health companies, of which 820 are biotech companies as of 2023. Out of these, 1 in 4 companies is working in oncology, and 21% of these French biotechs are developing to address rare diseases. Almost 50% of 2,600 companies are startups, and one-third have been around for more than 10 years.
UK Market Trends
As of May 2025, a total of 17 clinical trials related to microRNA as an intervention were registered on the clinicaltrials.gov website. The UK biotech sector reported a surge in funding of approximately $700 million in the third quarter of 2023. The UK biotech industry raised around £3.5 billion ($4.36 million) in 2024, an increase of 94% from 2023.
The Middle East & Africa are expected to grow at a considerable CAGR in the upcoming period with share of 4.40% in 2025. The biotech sector is booming at a rapid rate in the Middle East & African countries, such as the UAE, Saudi Arabia, and South Africa. Researchers are becoming aware of miRNA applications through conferences and workshops. Government bodies also support innovations in the biotech sector through favorable initiatives and funding programs. The increasing collaborations among key players expand the geographical presence of companies and strengthen their market position.
UAE Market Trends
The Ministry of Health and Prevention (MOHAP) announced mandatory genetic testing for people who are getting married through the premarital screening program. This helps couples prevent the chances of genetic diseases in their children. Dubai is set to host the “International Conference on Biomarkers and Clinical Medicine (ICBCM)” in December 2025. The conference will focus on multiple aspects, including cancer microRNA.
| Ecosystem Category | Representative Participants | Role in the Market |
| Technology Providers | Thermo Fisher Scientific, QIAGEN, Illumina, Takara Bio | PCR, NGS, sequencing platforms, reagents and workflow technologies |
| Product Manufacturers | Thermo Fisher Scientific, Merck KGaA, New England Biolabs, GeneCopoeia | miRNA isolation kits, qPCR assays, enzymes, probes, consumables |
| Service Providers | QIAGEN Genomic Services, Azenta Life Sciences, Eurofins Genomics | Sequencing, biomarker profiling, assay development, genomic analysis |
| Platform Providers | NanoString Technologies, Illumina, Standard BioTools (formerly Fluidigm) | Multiplex molecular profiling and genomic analysis platforms |
| CROs/CDMOs | Charles River Laboratories, ICON plc, WuXi AppTec | Preclinical research, biomarker validation, clinical development, manufacturing support |
| Software Vendors | QIAGEN Digital Insights, Illumina, SOPHiA GENETICS | Bioinformatics, genomic data interpretation, biomarker analytics |
| Research Institutions | NIH, MD Anderson Cancer Center, Broad Institute, Mayo Clinic | Discovery of novel miRNAs, translational research, clinical validation |
| End-User Industries | Biotechnology, Pharmaceuticals, Molecular Diagnostics, Academic Research, Clinical Laboratories | Drug discovery, diagnostics, biomarker development and translational medicine |
| Tier 1 | Tier 2 | Tier 3 | |
| Typical Market Influence | 68% | 24% | 8% |
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Thermo Fisher Scientific | Waltham, Massachusetts | USA | Broadest molecular biology portfolio and global leadership in miRNA workflows | TaqMan miRNA Assays, RNA extraction kits, qPCR, NGS solutions |
| QIAGEN | Venlo | Netherlands | Leading provider of sample preparation and molecular diagnostic technologies | miRNA isolation kits, QIAseq miRNA Library Kits, QIAcuity |
| Merck KGaA (MilliporeSigma) | Darmstadt, Hesse | Germany | Extensive genomics reagents and RNA research portfolio | miRNA reagents, RNA purification, CRISPR and genomics products |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| NanoString Technologies | Seattle, Washington | USA | Strong presence in RNA expression and biomarker profiling | nCounter miRNA Expression Assays |
| New England Biolabs | Ipswich, Massachusetts | USA | Widely used molecular biology enzymes and RNA research reagents | miRNA library preparation kits, enzymes |
| GeneCopoeia | Rockville, Maryland | USA | Specialized supplier of miRNA research products | miRNA mimics, inhibitors, vectors, assays |
| Tier 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| miRecule | Gaithersburg, Maryland | USA | Developer of microRNA-based therapeutics for rare diseases and oncology | RNA therapeutics, Antibody-RNA Conjugates |
| Regulus Therapeutics | San Diego, California | USA | Pioneer in miRNA therapeutics with clinical-stage programs | Anti-miR therapeutics |
| MiRXES | Singapore | Singapore | Commercial leader in miRNA liquid biopsy diagnostics in Asia | miRNA diagnostic assays |
By Products & Services
By Application
By End-use
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
